Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability and Food Effect of Lu AG06466 in Healthy Subjects
NCT05028673Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Aug 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ABX-1431 in post-traumatic stress disorder (PTSD), multiple sclerosis (MS) and focal epilepsy (4 arms), sponsored by Lundbeck. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity for Lu AG06466, Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity for Metabolite Lu AG06988 and 11 more. Started Aug 2021; status: completed.
02
Drugs
ABX-1431
03
Conditions
post-traumatic stress disorder (PTSD)multiple sclerosis (MS)focal epilepsy
Beyond the preview
Go deeper on NCT05028673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028673.